This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.To date, the most promising FDA approved clinical applications of 9-Tetrahydrocannabinol (THC) are for the control of chemotherapy associated nausea and vomiting and for appetite stimulation for AIDS patients suffering from anorexia as a result of wasting syndrome. THC also demonstrates other biological activities which lend themselves to possible additional therapeutic applications. Currently, the only FDA approved dosage form is an oral, soft gelatin capsule, that is expensive, results in inconsistent pharmacokinetic profiles, allows the drug to undergo extensive first-pass metabolism and exhibits undesirable side effects. This project will test the hypothesis that selected 9-THC pro-drugs incorporated into a hot-melt extruded Transmucosal Matrix Patch (TMP) delivery system will increase bioavailability of THC, following application to a subjects oral mucosa. Our approach in Aim 1 is to identify THC pro-drugs that are suitable for oral transmucosal delivery.
Aim 2 will include the formulation and production of preliminary THC pro-drug incorporated TMP systems, including testing and evaluation of the preliminary systems (in vitro) to determine lead formulations.
Aim 3 will involve the hot-melt extrusion, die-cutting and packaging of the lead systems, followed by bioadhesion, dissolution, permeability and stability testing to identify optimal TMP systems for each THC pro-drug. Optimized TMP formulations will be tested in an animal model in Aim 4 to determine pharmacokinetic profiles and confirm improved bioavailability. Incorporation of THC pro-drugs into a hot-melt extruded system as an alternate, more efficient method of delivery will have a tremendous impact on many chronically ill patients.
| Mohamed, Shaymaa M M; Elokely, Khaled M; Bachkeet, Enaam Y et al. (2015) New Glycosides and Trypanocidal Metabolites from Vangueria edulis. Nat Prod Commun 10:1897-900 |
| Radwan, Mohamed M; ElSohly, Mahmoud A; El-Alfy, Abir T et al. (2015) Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa. J Nat Prod 78:1271-6 |
| Tabrizian, Tahmineh; Hataway, Felicia; Murray, David et al. (2015) Prolylcarboxypeptidase gene expression in the heart and kidney: Effects of obesity and diabetes. Cardiovasc Hematol Agents Med Chem 13:113-23 |
| Ahmed, Safwat A; Ross, Samir A; Slade, Desmond et al. (2015) Minor oxygenated cannabinoids from high potency Cannabis sativa L. Phytochemistry 117:194-9 |
| Gómez-Betancur, Isabel; Cortés, Natalie; Benjumea, Dora et al. (2015) Antinociceptive activity of extracts and secondary metabolites from wild growing and micropropagated plants of Renealmia alpinia. J Ethnopharmacol 165:191-7 |
| Maddineni, Sindhuri; Battu, Sunil Kumar; Morott, Joe et al. (2015) Influence of process and formulation parameters on dissolution and stability characteristics of Kollidon® VA 64 hot-melt extrudates. AAPS PharmSciTech 16:444-54 |
| Morgan, J Brian; Liu, Yang; Coothankandaswamy, Veena et al. (2015) Kalkitoxin inhibits angiogenesis, disrupts cellular hypoxic signaling, and blocks mitochondrial electron transport in tumor cells. Mar Drugs 13:1552-68 |
| Malak, Lourin G; Ibrahim, Mohamed Ali; Bishay, Daoud W et al. (2014) Antileishmanial metabolites from Geosmithia langdonii. J Nat Prod 77:1987-91 |
| Tarawneh, Amer H; León, Francisco; Ibrahim, Mohammed A et al. (2014) Flavanones from Miconia prasina. Phytochem Lett 7:130-132 |
| Chatterjee, Arindam; Cutler, Stephen J; Doerksen, Robert J et al. (2014) Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening. Bioorg Med Chem 22:6409-21 |
Showing the most recent 10 out of 134 publications
